Scientific Advisors
Aisa Pharma’s Scientific Advisors are internationally recognized experts in systemic sclerosis, Raynaud’s phenomenon, vascular biology, and related fields. They provide independent scientific and clinical insight that informs our development strategy, study design, and endpoint selection.
Role of Our Advisors
Our advisors contribute to study design, patientrelevant endpoint selection, interpretation of emerging data, and publication strategy, helping to ensure that our programs are scientifically robust and clinically meaningful.
Scientific Advisory Board
Our Scientific Advisory Board (SAB) ensures that our programs address meaningful clinical questions and reflect the evolving standards of care in systemic sclerosis and associated vascular complications.
Tracy Frech, MD MSCI
Dr. Frech is the current President of the Scleroderma Clinical Trial Consortium, an Academic-Industry group that is the largest US based collaborative scleroderma research group and an Associate Professor in Rheumatology and Immunology at Vanderbilt University and Director of the Scleroderma Clinic. She previously directed the Scleroderma Clinic at the University of Utah for over fifteen years. Dr. Frech’s specific research interest is to better understand the natural history of symptomatic vasculopathy in SSc. Dr. Frech also focuses on improvements in diagnosis and treatment of SSc through meticulous patient phenotyping as well as outcome definitions and data standardization for effectively monitoring and treating SSc patients.
Robyn Domsic, MD
Dr. Robyn T. Domsic, MD, MPH, is an Associate Professor of Medicine at the University of Pittsburgh and Clinical Director of the UPMC Scleroderma Center, specializing in rheumatology and scleroderma. She focuses on improving patient care through risk stratification, vascular imaging, and researching Raynaud’s Phenomenon.
Francesco Del Galdo, MD, PhD
Professor Francesco Del Galdo, MD, PhD, is a leading rheumatologist and Head of the Scleroderma Programme at the University of Leeds. Specializing in systemic sclerosis (scleroderma), he pioneered the use of Optical Coherence Tomography (OCT) for skin fibrosis, has secured over £3 million in research funding, and published over 120 peer-reviewed papers on autoimmune diseases. He is the past President of EUSTAR, the world’s largest collaborative Scleroderma Research and Trial group.
Jerry Molitor, MD, PhD
Dr. Jerry Molitor, MD, PhD, is a rheumatologist and Associate Professor of Medicine at the University of Minnesota Medical School, specializing in scleroderma and rheumatoid arthritis. He directs the multi-disciplinary scleroderma clinic at the University of Minnesota, focusing on autoimmune research and has been recognized as a top doctor in the Twin Cities and nationally. Dr. Molitor has clinical research interests in Early Rheumatoid Arthritis and Systemic Sclerosis pathogenesis and disease prevention, and has been a consultant or investigator in multiple trials of candidate therapies for these conditions. His translational research focuses on understanding the interplay between impaired immune responses to infections and associated autoimmunity.
John Pauling, BMedSci, BMBS, PhD, FRCP
John Pauling is a rheumatologist at North Bristol NHS Trust in the UK and honorary associate professor of rheumatology at the University of Bristol Medical School. His major research interests are Raynaud’s phenomenon and digital vasculopathy in the autoimmune rheumatic diseases. He has an interest in outcome measures and clinical trial design in systemic sclerosis and related disorders. John co-chairs the OMERACT digital vascular SIG. He co-chairs the SCTC industry roundtable. John is the principal author of the newest Raynaud’s patient recorded outcome measure assessment tool, the ASRAP.
